Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
David C. Hastings | Chief Financial Officer | 2025-02-04 | 22,183 | $3.28 | $72.83kSell |
Michael J. McElhaugh | Interim President CEO | 2025-02-04 | 23,790 | $3.28 | $78.10kSell |
J. Christopher Naftzger | General Counsel and CCO | 2025-02-04 | 11,333 | $3.28 | $37.21kSell |
Karen Sims | Chief Medical Officer | 2025-02-04 | 19,348 | $3.28 | $63.52kSell |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Matthew Gline | 20.26% | 38,847,462 | $170.93M | Insider |
Roivant Sciences Ltd | 20.26% | 38,847,462 | $170.93M | Insider |
Dexxon Holdings Ltd | 16.71% | 32,027,080 | $140.92M | Insider |
Morgan Stanley | 12.60% | 24,162,383 | $106.31M | Institution |
Vivek Ramaswamy | 8.38% | 16,068,455 | $70.70M | Insider |
Svf Investments Uk Ltd | 8.35% | 16,013,540 | $70.46M | Insider |
Rose Sharon Shabet | 8.35% | 16,013,540 | $70.46M | Insider |
Patrick MacHado | 8.35% | 16,013,540 | $70.46M | Insider |
Dexcel Pharma Technologies Ltd | 8.35% | 16,013,540 | $70.46M | Insider |
Viking Global Equities Master Ltd | 8.35% | 16,013,540 | $70.46M | Insider |